Literature DB >> 24709692

Whole-genome analysis of a patient with early-stage small-cell lung cancer.

J-Y Han1, Y-S Lee2, B C Kim3, G K Lee1, S Lee4, E-H Kim5, H-M Kim6, J Bhak4.   

Abstract

We performed whole-genome sequencing (WGS) of a case of early-stage small-cell lung cancer (SCLC) to analyze the genomic features. WGS revealed a lot of single-nucleotide variations (SNVs), small insertion/deletions and chromosomal abnormality. Chromosomes 4p, 5q, 13q, 15q, 17p and 22q contained many block deletions. Especially, copy loss was observed in tumor suppressor genes RB1 and TP53, and copy gain in oncogene hTERT. Somatic mutations were found in TP53 and CREBBP. Novel nonsynonymous (ns) SNVs in C6ORF103 and SLC5A4 genes were also found. Sanger sequencing of the SLC5A4 gene in 23 independent SCLC samples showed another nsSNV in the SLC5A4 gene, indicating that nsSNVs in the SLC5A4 gene are recurrent in SCLC. WGS of an early-stage SCLC identified novel recurrent mutations and validated known variations, including copy number variations. These findings provide insight into the genomic landscape contributing to SCLC development.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24709692     DOI: 10.1038/tpj.2014.17

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  2 in total

1.  CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.

Authors:  Zach A Dixon; Lindsay Nicholson; Martin Zeppetzauer; Elizabeth Matheson; Paul Sinclair; Christine J Harrison; Julie A E Irving
Journal:  Haematologica       Date:  2016-12-15       Impact factor: 9.941

2.  Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis.

Authors:  Jia Zhong; Qiwen Zheng; Tongtong An; Jun Zhao; Meina Wu; Yuyan Wang; Minglei Zhuo; Jianjie Li; Xinghui Zhao; Xue Yang; Bo Jia; Hanxiao Chen; Zhi Dong; Jingjing Wang; Yujia Chi; Xiaoyu Zhai; Ziping Wang
Journal:  Thorac Cancer       Date:  2019-07-18       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.